Chicago, Ill., Sept. 22, 2017 — Complementing the acclaimed talent already assembled on its scientific leadership team, bioprinting startup BIOLIFE4D announced the addition of Raimond Winslow, Ph.D. whose vast expertise will help the company deliver on its mission to 3D bioprint a viable human heart suitable for transplant.
Winslow’s new role at BIOLIFE4D comes in addition to the leadership positions he holds at Johns Hopkins University where he is Founding Director of the Institute for Computational Medicine, and the Raj and Neera Singh Professor of Biomedical Engineering .
He earned a B.S. in electrical engineering from Worcester Polytechnic Institute and a Ph.D. in biomedical engineering from Johns Hopkins. He concluded his training at the Institute for Biomedical Computing and Department of Neurology within Washington University in St. Louis. He joined the faculty of Johns Hopkins in 1991 as an assistant professor, became an associate professor in 1994 and a full professor in 2000.
“Dr. Winslow is seasoned veteran of computational medicine and biomedical engineering and he will play a key role in the optimization of our bioprinting and tissue engineering processes,” said BIOLIFE4D CEO Steven Morris. “We are delighted to have him join the rest of our world-class scientific team, and ultimately our crowdfunding partners, as we look to transform the treatment of heart disease.”
Winslow is a fellow of the Biomedical Engineering Society, American Heart Association and American Institute for Medical and Biological Engineering. He serves as Specialty Editor in Chief for the journal Frontiers in Computational Physiology and Medicine, and as a member of the editorial boards of Circulation Research, The Journal of Molecular and Cellular Cardiology, IET Systems Biology and the International Journal of Computational Medicine and Healthcare.
He has authored or co-authored more than 130 peer-reviewed articles and 12 book chapters, received numerous grants and awards and holds one patent.
With the goal of making organ replacement commercially viable and commonplace globally, BIOLIFE4D’s approach will combine recent breakthroughs in regenerative medicine, stem cell biology, 3D printing techniques and computing technology. The company will leverage the power of equity crowdfunding – accepting investments from the masses – to raise capital and help accomplish its objectives.
“Working with BIOLIFE4D is an incredible opportunity to partner with some of the brightest minds in medicine and biomedical engineering, as well as a vast community of investors, as we look to deliver on the promise of bioprinting,” said Winslow. “It’s exciting to consider how BIOLIFE4D’s proposed, commercially viable bioprinting process could revolutionize the medical community approaches advanced heart disease, one of the world’s deadliest ailments.”
Winslow’s colleagues at BIOLIFE4D include science advisory team leader Adam Feinberg, Ph.D. from Carnegie Mellon University, Ibrahim Ozbolat, Ph.D. from Penn State University, Sean Palecek, Ph.D. from the University of Wisconsin at Madison, Shayn Peirce-Cottler, Ph.D. from the University of Virginia, Ramille Shah, Ph.D. from Northwestern University and Janet Zoldan, Ph.D. from the University of Texas in Austin. In addition, accomplished thoracic and cardiac surgeon Jeffrey Morgan M.D., FACS, FACC from the Texas Heart Institute joins the team as Chief Medical Officer.
Today’s announcement is the latest in a series of strategic moves made by BIOLIFE4D recently, including the launch of an equity crowdfunding campaign. BIOLIFE4D recently filed a $50 million initial public offering with the Securities and Exchange Commission (SEC) under Regulation A+ equity crowdfunding rules, allowing everyday investors to help the company bring its groundbreaking cardiac tissue regeneration and organ replacement process to market.
To learn more about BIOLIFE4D and to express interest in investing visit https://biolife4d.com/invest/.
BIOLIFE4D is a pioneering biotech company laser focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant – lifesaving technology that gives patients the gift of time. With BIOLIFE4D, a patient-specific, fully functioning heart will be created through 3D bioprinting using the patient’s own cells – eliminating the well-known challenges of organ rejection and long donor waiting lists that plague existing organ transplant methods. Financed through equity crowdfunding, BIOLIFE4D is driving a movement to transform the treatment of heart disease, the leading cause of death among both men and women globally. Learn more and invest at www.biolife4d.com. Follow us on Facebook and Twitter @BIOLIFE4D.
Although you are currently able to express your interest in investing, BIOLIFE4D Corporation is not yet accepting investments. No money or other consideration is being solicited by the company at this time, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement is qualified, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance given after the qualification date. If you indicate interest, your indication of interest involves no obligation or commitment of any kind.